Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016

  • ID: 3981276
  • Report
  • 463 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • Arvinas Inc
  • CellCentric Ltd
  • F. Hoffmann-La Roche Ltd
  • Medivation Inc
  • Sotio as
  • MORE
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016

Summary

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline landscape.

Metastatic hormone refractory prostate cancer (mHRPC), also known as metastatic androgen independent prostate cancer or metastatic castrate-resistant prostate cancer is characterized by rising prostate specific antigen (PSA) with a low testosterone and is associated with poor prognosis. mHRPC arises when prostate cancer becomes non-responsive to hormone therapy and spreads to neighboring tissues or to other parts of the body such as the bones. Some of the most important predisposing factors for mHRPC include increasing age, environmental stress and genetic factors. Symptoms of mHRPC may include lethargy, paraplegia, bone pain, lower back or pelvic pain and weight loss. It may be controlled by hormonal therapy, radiation therapy or chemotherapy.

Report Highlights

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 6, 37, 20 and 19 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 4 and 1 molecules, respectively.

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • Arvinas Inc
  • CellCentric Ltd
  • F. Hoffmann-La Roche Ltd
  • Medivation Inc
  • Sotio as
  • MORE
Introduction

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview

Therapeutics Development

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment

Drug Profiles

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2016

Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Development by Companies, H2 2016 (Contd..2)

Number of Products under Development by Companies, H2 2016 (Contd..3)

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Development by Companies, H2 2016 (Contd..3)

Products under Development by Companies, H2 2016 (Contd..4)

Products under Development by Companies, H2 2016 (Contd..5)

Products under Investigation by Universities/Institutes, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AB Science SA, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AbbVie Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corp, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Advaxis Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ambrx Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Amgen Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Armour Therapeutics Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ArQule Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Arvinas Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Asana BioSciences LLC, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AstraZeneca Plc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ATLAB Pharma SAS, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by BeiGene Ltd, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Celgene Corp, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CellCentric Ltd, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Clovis Oncology Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Corcept Therapeutics Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Curevac AG, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by DexTech Medical AB, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Endocyte Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ESSA Pharma Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Gilead Sciences Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Glactone Pharma AB, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GTx Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ionis Pharmaceuticals Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Johnson & Johnson, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by MedImmune LLC, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medivation Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by MEI Pharma Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by NewLink Genetics Corp, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Novartis AG, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncogenex Pharmaceuticals Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncolytics Biotech Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Pfizer Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Progenics Pharmaceuticals Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Selexel, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Sotio as, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Supratek Pharma Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tesaro Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Threshold Pharmaceuticals Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tiltan Pharma Ltd, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tokai Pharmaceuticals Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by TRACON Pharmaceuticals Inc, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by UbiVac LLC, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Viralytics Ltd, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Zenith Capital Corp, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..1), H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..2), H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..3), H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..4), H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products, H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products (Contd..1), H2 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products (Contd..2), H2 2016

List of Figures

Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2016

Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Top 10 Routes of Administration, H2 2016

Number of Products by Stage and Top 10 Routes of Administration, H2 2016

Number of Products by Top 10 Molecule Types, H2 2016

Number of Products by Stage and Top 10 Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AB Science SA
  • AbbVie Inc
  • Adamis Pharmaceuticals Corp
  • Advaxis Inc
  • Ambrx Inc
  • Amgen Inc
  • Aptevo Therapeutics Inc
  • Armour Therapeutics Inc
  • ArQule Inc
  • Arrowhead Pharmaceuticals Inc
  • Arvinas Inc
  • Asana BioSciences LLC
  • AstraZeneca Plc
  • ATLAB Pharma SAS
  • Aurigene Discovery Technologies Ltd
  • Bavarian Nordic A/S
  • BeiGene Ltd
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corp
  • CellCentric Ltd
  • Clovis Oncology Inc
  • Corcept Therapeutics Inc
  • Corvus Pharmaceuticals Inc
  • Curevac AG
  • DexTech Medical AB
  • Eli Lilly and Company
  • Endocyte Inc
  • ESSA Pharma Inc
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Glactone Pharma AB
  • GlaxoSmithKline Plc
  • GTx Inc
  • Ionis Pharmaceuticals Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • MedImmune LLC
  • Medivation Inc
  • MEI Pharma Inc
  • Millennium Pharmaceuticals Inc
  • NewLink Genetics Corp
  • Novartis AG
  • Oncogenex Pharmaceuticals Inc
  • Oncolytics Biotech Inc
  • Ono Pharmaceutical Co Ltd
  • Pfizer Inc
  • Progenics Pharmaceuticals Inc
  • Selexel
  • Sotio as
  • Supratek Pharma Inc
  • Taiho Pharmaceutical Co Ltd
  • Takeda Pharmaceutical Company Ltd
  • Tesaro Inc
  • Threshold Pharmaceuticals Inc
  • Tiltan Pharma Ltd
  • Tokai Pharmaceuticals Inc
  • TRACON Pharmaceuticals Inc
  • UbiVac LLC
  • Viralytics Ltd
  • Zenith Capital Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll